Resum
Diabetic retinopathy is now an important cause of visual impairment in the developing countries due to changing lifestyles. This review includes recent developments on the pathogenesis of diabetic retinopathy emphasizing the role of Protein Kinase C and Vascular Endothelial Growth Factor. It also bring to the fore the atypical presentations, recent use of pharmacological agents and the importance of screening in the management of diabetic retinopathy. These developments are relevant in Nigeria, and Ophthalmic and Medical practitioners need to be aware.
Keywords: Pathogenesis, protein kinaseC, vascular endothelial growth factor, atypical presentations, screening, diabetic retinopathy.
Résumé
Aujourd’hui, la rétinopathie diabétique est un important cause de impair visuel dans les pays sous développés du aux changements du style de vie. Cette revue inclut les développements récents sur la pathogenèse de la rétinopathie diabétique supportant le rôle de la Protéine Kinase C et du facteur de croissance endothéliale vasculaire. Ceci ressort des présentations atypiques, L’usage récent des agents pharmacologiques et l’importance du dépistage dans les soins de la rétinopathie diabétique. Ces développements sont importants au Nigeria, et les personnels ophtalmologiques et médicaux doivent tirer une attention.
Correspondence: Dr. T.S. Oluleye, Retina and Vitreous Unit, Department of Ophthalmology, University College Hospital, P.M.B. 5116, Ibadan, Nigeria. E-mail: t_oluleye@yahoo.co.uk
Referències
WHO, IDF, WESDR, Kempen JH et al Arch Ophth, 2004; 122: 552-563
World Diabetes Foundation : Annual Review 2002 (ed Meyer AH), Videback Bogtrykken : Lyngby, Denmark
King H, Aubert RE and Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care, 1998, 21: 1414-1431.
Dandona L, Dandona R, Naduvilath T.J et al.
Population based assessment of diabetic retinopathy in an urban population in southern India.Br J Ophthalmol. 1999; 83(8): 937-940.
Nwosu SN. Diabetic Retinopathy in Nnewi, Nigeria. Nig. J. Ophthamol. 2000; 8(1) : 7-10.
Nwosu SN. Low vision in Nigerians with diabetes mellitus. Doc. Ophthalmol. 2000; 101 (1) :51-57.
Mohan KC, Shukla D and Kim R. Retinal Vascular Disorders. Academia Publishers, New Delhi Feb 2005.
Uhlmann K, Kovacs P, Boettcher Y, Hammes P and Paschke R. Genetics of Diabetic Retinopathy. Exp. Clin. Endocrinnol. Diab. 2006; 114: 275-294.
Awata T, Inoue K, Kurihara S, Ohukubo T, Watanabe M and Inukai K, Inoue I and Katayama S. A common polymorphism in the 5’- untranslated region of VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 2002; 51: 1635- 1639.
Sheetz MJ and King GL: Molecular understanding of hyperglycemia’s adverse effects for diabetic complications. JAMA, 2002; 288: 2579 –2588.
Mellor H and Parker PJ: The extended protein kinase C superfamily. Biochem J, 1998 332: 281–292.
Bullock WH, Magnuson SR, Choi S, Gunn DE and Rudolph J: Prospects for kinase activity modulators in the treatment of diabetes and diabetic complications. Curr Top Med Chem, 2002; 2: 915–938.
Aiello LP, Bursell S-E, Clermont A, Duh E, Ishii H, Takagi C, Mori F, Ciulla TA, Ways K, Jirousek M, Smith LEH and King GL: Vascular endothelial growth factor–induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective _-isoform–selective inhibitor. Diabetes, 1997; 46: 1473–1480.
Xu X, Zhu Q, Xia X, Zhang S, Gu Q and Luo D: Blood-retinal barrier breakdown induced by activation of protein kinase C via vascular endothelial growth factor in streptozotocin-induced diabetic rats. Curr Eye Res, 2004; 28: 251–256.
Danis RP, Bingaman DP, Jirousek M and Yang Y: Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKC _ inhibition with LY333531. Invest Ophthalmol Vis Sci., 1998; 39: 171–179.
Aiello LP, Bursell SE, Devries T, Alatorre C, King GL and Ways DK: Amelioration of abnormal retinal hemodynamics by a protein kinase C _ selective inhibitor (LY333531) in patients with diabetes: results of a phase 1 safety & pharmacodynamic clinical trial. Invest Ophthalmol Vis Sci. 1999; 40:S192.
Funatsu H, Yamashita H, Ikeda T, Nakanishi Y, Kitano S and Hori S: Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthalmol. 2002; 133: 537–543.
Donnelly R, Idris I and Forrester J. Role of protein kinase in diabetic retinopathy. Br J Ophthalmol. 2004; 88: 145-151.
Michaelson IC. The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal diseases. Trans Ophthalmol Soc U K 1948; 68: 137-180
Sivalingam A, Kenney J, Brown GC, Benson WE and Donoso L. Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol 1990;108: 869-872.
Meyer-Schwickerath R, Pfeiffer A, Blum WF, et al. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease: studies in nondiabetic and diabetic subjects. J Clin Invest 1993; 92: 2620-2625.
Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluids of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-1487.
Adamis AP, Miller JW, Bernal M-T, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994;118: 445-450.
Ramsey DJ, Ripps H and Qian H. An electrophysiological study of retinal function in the diabetic female rat. Invest. Ophthalmol. Vis. Sci. 2006 ; 47(11): 5116-5124.
Wilkinson CP, Ferris FL,Klein RE et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthamology.2003; 110: 1677-1682.
Aiello LP, Catrill MT and Wong JS. Systemic considerations in the management of diabetic retinopathy. Am J Ophthalmol 2001; 132:760-776.
Skyler JS. Medical management of diabetic retinopathy. In Ophthalmology Mono 14: Diabetes and ocular disease: past, present and future therapies (ed., Flynn HW, Smiddy WE) San Francisco. The Foundation of the American Academy of Ophthalmology 2000; p 181-201
Diabetic retinopathy study research group. Photocoagulation treatment of proliferative diabetic retinopathy:second report. Ophthalmology 1978;85:82-106.
Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for macular edema. Early Treatment Diabetic Retinopathy Study report 1. Arch Ophthalmol 1985; 103: 1796-1806.
Martidis A, Duker J, Greenberg PB et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002; 109:920-927.
Avci R, Kaderli B and Akalp F. Intravitreal triamcinolone injection for chronic diffuse macular edema. Clin. Exp. Ophthalmol 2006; 34: 27-32.
Jonas JB, Kreissig I, Sofker A and Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003;121: 57-61.
Jonas JB and Sofker A. Intravitreal injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol.2001; 132: 425-427
Jonas JB, Akkoyun I, Kreissig I, et al. Diffuse diabetic macular edema treated by intravitreal triamcinolone acetonide : a prospective comparative non randomized study. Br J. Ophthalmol 2005; 89: 321-326.
Massin P, Andren F, Haouchine B et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology. 2004; 111: 218-224.
Sutter FKP, Simpson JM and Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment. Three month efficacy and safety results of a prospective randomized, double masked, placebo-controlled clinical trial. Ophthalmology 2004; 111: 2044-2049.
Bardak Y, Cekic O and Tig SU. Comparison of ICG- assisted ILM peeling and triamcinolone- assisted posterior vitreous removal in diffuse diabetic macular edema. Eye, 2006;20:1357-1359.
Avery R, Pearlman J, Pieramici D, Rabena M, et al. Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic Retinopathy. Ophthalmology 2006;113:1695–1705.
Chun DW, Heier JS,Topping TM, Duker JS and Bankert JM. A pilot study of multiple intravitreal injections of Ranibizumab in patients with center involving clinically significant macular edema. Ophthalmology 2006 Oct; 113(10) 1706-1712.
The PKC-DRS Study Group* The Effect of Ruboxistaurin on Visual Loss in Patients with Moderately Severe to Very Severe Nonproliferative Diabetic Retinopathy. Initial Results of the Protein Kinase C beta_ Inhibitor Diabetic Retinopathy Study (PKC-DRS) Multicenter Randomized Clinical Trial Diabetes 2005; 54:2188–2197.
Grant M, Mames R, Fitzgerald C, Hazariwah K et al. The efficacy of Octreotide in the therapy of severe non proliferative and early proliferative diabetic retinopathy. Diabetes care. 2000; 23: 504-509.
Rosenblatt BJ and Benson WE. Diabetic retinopathy. In: Yanoff M, Duker J.S et al (editors). Ophthalmology. St Louis, Mosby. 2nd edition. 2004; p:878.
Davis M.D and Blodi B.A. Proliferative diabetic retinopathy. In: Ryan S.J, Schachat A.P, Hengst editors. Retina. 3rd edition. St. Louis Mosby, 2001; P:1309-1349
Christoforidis JB and D Amico DJ. Surgical and other treatments of diabetic macular edema. Int Ophthalmol Clin 2004; 139-160
Smiddy WE and Flynn HW. Vitrectomy for diabetic retinopathy. In. diabetes and Ocular Disease : Past, present and future therapies (eds: Flynn HW, Smiddy WD) San Francisco. The Foundation of the American Academy of Ophthalmology 2000, pp 155-175.
Proceedings from the Diabetic Retinopathy Conference, Aravind Eye Hospital, Madurai, January, 2007.